Source: ChatGPT KI generiert

Merck KGaA – The billion-euro drug faces competition

A successful medicine can generate high profits for years. But as soon as patent protection weakens, the unpleasant part of the business often begins for pharmaceutical companies. At Darmstadt-based Merck KGaA, this is currently evident with the multiple sclerosis medicine Mavenclad. The active ingredient cladribine has become established as a treatment for certain relapsing forms of the disease. In the US, generic competition is now increasingly emerging.

The consequences have already been factored into the forecast. As a precaution, Merck expects no further US sales of Mavenclad for November and December. At the same time, the rest of the business is performing better than expected. Last week, the group raised its full-year forecast for the third time this year.

In the third quarter, revenue rose 5.8% to EUR 5.6 billion. Adjusted EBITDA reached EUR 1.7 billion. For the full year, management now expects revenue of between EUR 21.5 billion and EUR 21.9 billion and EBITDA before exceptional items of EUR 6.2 billion to EUR 6.4 billion.

The Life Science and Electronics divisions in particular are delivering growth. This enables Merck to partly offset pressures on its pharmaceutical business.

Analysts remain cautious despite the raised forecast. Jefferies maintained its Hold rating with a price target of EUR 144. UBS also maintained its Neutral or Hold rating and a target of EUR 150. Bernstein, by contrast, raised its price target from EUR 151 to EUR 178, but maintained its Neutral rating.

BioNxt Solutions – Patent success and the next step towards clinical trials

A proven active ingredient, but a new dosage form. BioNxt Solutions aims to simplify the treatment of multiple sclerosis. The Canadian biotechnology developer is working on BNT23001, a thin, cladribine oral dissolvable film (ODF) that dissolves under the tongue. This could make administration significantly easier, particularly for patients with swallowing difficulties.

Cladribine is already approved as the active ingredient in Merck’s MS medicine Mavenclad. BioNxt is developing an independent formulation intended to enable comparable absorption of the active ingredient. There is no collaboration with Merck.

In October, the company reached two important milestones. Around 1,500 trial films were manufactured under GMP conditions. This was followed on October 16 by the submission of the European clinical trial application. BioNxt had already completed the required investigational medicinal product dossier in August.

The planned trial in healthy adults is intended to investigate whether BNT23001 is comparable to Mavenclad in terms of active ingredient absorption and bioequivalence. Earlier preclinical studies provided supporting results. Regulatory approval and the final release of the trial films are still pending.

Another positive is patent protection. Since March 2026, BioNxt has held a European unitary patent effective in 18 EU countries, including Germany and France, for its cladribine ODF technology.

For the next development steps, BioNxt announced a private placement of up to CAD 2.5 million. Plans envisage 10 million units at CAD 0.25, each consisting of one share and one warrant.

With GMP manufacturing complete, the clinical trial application submitted, and the European patent granted, BioNxt has met key prerequisites for further clinical development.

Novartis – New trial data increase the pressure

While Merck is battling generic competition and BioNxt is developing an alternative cladribine formulation, Novartis is already working on the next generation of MS therapies. The Swiss pharmaceutical group has an established medicine in Kesimpta and could add another active ingredient to its portfolio in future.

The focus is on remibrutinib. The oral BTK inhibitor has delivered positive results in two Phase III trials for relapsing multiple sclerosis. Compared with the comparator medicine teriflunomide, the active ingredient significantly reduced the annualised relapse rate. MRI scans also showed lower disease activity.

According to the company, more than 92% of treated patients remained free of confirmed disability progression at 6 months during the period studied. However, a statistically significant advantage for this endpoint was not demonstrated in all analyses. Regulatory approval is also still pending.

Kesimpta demonstrates that the MS market is already a significant business for Novartis. In the third quarter, sales of the medicine rose by 22% at constant currencies.

The group as a whole is also growing. Quarterly revenue rose 4% at constant currencies, while adjusted operating profit increased 10%. The corresponding full-year profit forecast was raised. However, an impairment charge on another development project weighed on results.

Novartis thus has a combination of existing revenue and advanced research. The positive remibrutinib data could strengthen its competitive position in the MS market, provided the active ingredient is approved.

Conclusion

Merck must manage the generic pressure on Mavenclad, but can draw on a broadly diversified business. BioNxt Solutions is attempting to find its own place in the market with a new cladribine dosage form. Novartis is relying on growing sales of Kesimpta and new active ingredients such as remibrutinib. While the major pharmaceutical groups are already earning billions, BioNxt still faces crucial clinical trials.


Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.

More From The Market Online

Shock at Deutz! Opportunity at Evotec? Buy recommendation for Desert Gold!

Created and Published on Behalf of Desert Gold Ventures Inc.Shock at Deutz! After the share price plunged from over EUR 13, a short-seller attack…

Volatile markets: Opportunities in Micron Technology, Strategic Resources and Mercedes-Benz

Anthropic's stock market flotation is currently overshadowing everything in the markets and even appears to be pushing the scandal surrounding Nvidia CEO Jensen Huang…

Power for Starlink in Remote Areas: HPQ Silicon pits 80 hours against SpaceX – Enovix shows where the silicon battery market is growing

Created and published on behalf of HPQ SiliconUntil now, anyone needing a reliable internet connection far from civilisation faced a major challenge: where does…

Trump Meets Xi: China’s Resource Dominance Puts Pressure on the West – MP Materials, Antimony Resources and Energy Fuels in Focus

Created and Published on Behalf of Antimony Resources Corp.Donald Trump wants to end the USA's economic dependence on China. Yet it is precisely in…